Axalta agrees to all-stock merger of equals with AkzoNobel
Axalta and AkzoNobel agreed on November 18, 2025 to combine in an all-stock merger of equals, creating a company with an enterprise value of approximately $25 billion. Each Axalta common share would convert into 0.6539 AkzoNobel ordinary shares, and Axalta shareholders would own 45% of the combined company after closing. The deal requires shareholder and regulatory approvals, is expected to close in late 2026 to early 2027, and both companies have suspended their share buyback programs.
Key points
- Each Axalta common share would receive 0.6539 AkzoNobel ordinary shares.
- Axalta shareholders would own 45% and AkzoNobel shareholders 55% of the combined company on a pro forma basis.
- The companies expect approximately $600 million in run-rate cost synergies, with 90% achieved within three years after closing.
- Closing is expected in late 2026 to early 2027; both companies suspended share buybacks effective immediately.
The filing
Written by AI (Anthropic Claude, claude-haiku-5-5) on Nov 8, 2026, 12:57 AM ET, from the text of the filing and its press-release exhibits only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on November 18, 2025.
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.